ATTR-CM treatment is difficult, in most cases, but diflunisal is a promising treatment option for wild-type ATTR-CM. Treatment options for transthyretin amyloid cardiomyopathy (ATTR-CM) have historically been either risky or lacking in long-term efficacy. Treating…
Daysha RobinsonNovember 16, 2022
Diagnosing ATTR-CM is usually a difficult and potentially dangerous process, but non-invasive novel modalities could significantly reduce the risk. Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative disease characterized by deposits of amyloid fibrils. It tends…
Daysha RobinsonNovember 14, 2022
ATTR-CM can only be treated in a limited number of ways, and this article analyzes and compares the currently available treatment options. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, debilitating disease with high mortality. ATTR-CM…
Daysha RobinsonNovember 14, 2022
With a minimal incidence of amyloid recurrence in the cardiac allograft, cardiac transplantation is well tolerated, increases functional ability, and lengthens survival in patients with ATTR-CM, according to a 30-year retrospective study. ATTR-CM should be…
Daysha RobinsonNovember 9, 2022
In patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), tafamidis was associated with a lower rate of CV-related hospitalizations and a shorter stay. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an underdiagnosed disease characterized by deposits of improperly folded…
Daysha RobinsonNovember 9, 2022
Emboli are a common complication of amyloid transthyretin cardiomyopathy (ATTR-CM). This study found that the CHA2DS2-VASc score is not useful in predicting embolic events in ATTR-CM patients with or without AF, and that VKAs and…
Daysha RobinsonNovember 9, 2022
A recent study examined the confounding effect of mortality on the frequency of CV-related hospitalization in patients in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). The impact of tafamidis on CV-related hospitalization was underestimated…
Daysha RobinsonNovember 1, 2022
In patients stabilized on tafamidis, SGLT2 inhibitors may be beneficial for improving outcomes of transthyretin amyloid cardiomyopathy (ATTR-CM). Treatment with dapagliflozin was found to be well-tolerated in patients with ATTR-CM. Transthyretin amyloid cardiomyopathy (ATTR-CM) is…
Daysha RobinsonOctober 27, 2022
Researchers investigated geographic disparities in heart failure outcomes in states with the highest and lowest life expectancies. Disparities in heart failure mortality and incidence, as well as the decline in survival rates of heart failure…
Daysha RobinsonSeptember 15, 2022
Patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM) are at risk of cardiovascular comorbidities, including atrial fibrillation and flutter. Routine ambulatory monitoring in patients with ATTR-CM could help drive the use of anticoagulation to prevent strokes. Heart…
Daysha RobinsonSeptember 15, 2022